Our new ESG website is live! At Innovent, our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals drives us to integrate ESG principles into every aspect of our value chain. We are dedicated to ensuring the highest quality in our products, while also caring for our people and the environment. Discover more about our commitment to Environmental, Social and Governance (ESG) initiatives on our newly launched website: https://lnkd.in/gzQrv-gW #ESG #Sustainability #Healthcare #InnoventBiologics
Innovent Biologics
制药业
Suzhou,Jiangsu 21,463 位关注者
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.
关于我们
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 10 products in the market. It has 3 new drug applications under regulatory review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
- 网站
-
http://www.innoventbio.com
Innovent Biologics的外部链接
- 所属行业
- 制药业
- 规模
- 5,001-10,000 人
- 总部
- Suzhou,Jiangsu
- 类型
- 上市公司
- 创立
- 2011
- 领域
- Biologics Manufacturing、Monoclonal Antibodies、Biosimilars和Novel Drugs
地点
Innovent Biologics员工
-
Stephen Lau
Biotech C-Suite Executive and Board Member | Entrepreneur | Focused on Fundraising & Deal-making | Company Formation | Passionate about Many Things…
-
赵文利
-
Jia Duo
Sr. Director at Innovent Biologics(信达生物制药)
-
Blake Salisbury
Senior Vice President of Business Development at Innovent Biologics
动态
-
We are thrilled to announce that Innovent has been recognized in Universum's "2024 China's Most Attractive Employers Rankings"! 🏅 10th Position as the Most Attractive Employer for natural science students 🏅 19th Position as the Most Attractive Employer for health/medicine students 🏅 Top 100 Most Attractive Employers for engineering students This achievement highlights our commitment to innovation, mentorship, excellence in cutting-edge research and therapies, strong corporate social responsibility and our inspiring mission and vision. We're grateful to our incredible team and community for making this possible. Together, we are creating a supportive workplace, prioritizing employee wellness, and inspiring our team to make a positive difference in healthcare. #InnoventBiologics #Healthcare #Universum2024
-
Our team had the incredible opportunity to give an oral presentation at ESMO GI in Munich. We shared the latest Phase 1 clinical data of our innovative anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ AC). The results demonstrate that IBI343 has promising efficacy and a favorable safety profile in patients with G/GEJ AC whose tumors express CLDN18.2. We’re proud to be pushing the boundaries of cancer treatment and improving patient outcomes. https://lnkd.in/gujfiyyv #ESMOGI2024 #ClinicalTrials #InnoventBiologics #Oncology
-
At #ADA2024 and during our recent investor call, Innovent presented the promising results of the GLORY-1 Phase 3 clinical trial for the GLP-1R/GCGR dual agonist mazdutide, along with updates on our general biomedicine pipeline. See the exciting results here:https://lnkd.in/gPrQhh8S
-
We're especially thrilled to share the GLORY-1 Phase 3 study results of liver fat content in Chinese adults with overweight or obesity at the #ADA Scientific Sessions 2024. This clinical trial of mazdutide brings us closer to offering improved treatment options for those with metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD). https://lnkd.in/gdXTAxKp
-
Exciting news from the ADA Scientific Sessions 2024! Our team presented the key results from the first Phase 3 clinical trial of the GLP-1R/GCGR dual agonist mazdutide in Chinese adults with overweight or obesity, where GLORY-1 met all primary and key secondary endpoints, showcasing robust weight loss, reduced liver fat content, and improvements in multiple cardiometabolic risk factors. https://lnkd.in/gtzSRyC6 #ADA2024 #InnoventBiologics
-
We’re glad to share the positive data from our oncology pipeline update at today's investor meeting. Encouraged by the progress we're making in cancer treatment. https://lnkd.in/gtE7VKYu #Oncology #innoventbiologics
-
We are pleased to invite investors, analysts and stakeholders to participate in our conference call on June 25, highlighting clinical updates from our general biomedicine product line. Registration required at the link below. https://lnkd.in/gcgmSBv6
-
Innovent is presenting clinical data on our first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein (IBI363) at the 2024 ESMO Virtual Plenary, June 13-14. Read below about this antibody's promising safety signals, its broad anti-tumor activity and its applicability across tumor types. #ESMOVirtualPlenary #oncology #InnoventBiologics https://lnkd.in/guaqFQmN
-
We're pleased to announce that Innovent's TOPO1i anti-CLDN18.2 ADC (IBI343) has received Fast Track Designation from the FDA for advanced pancreatic cancer. We're thrilled to be closer to offering an innovative treatment option for one of the most challenging cancers to treat. https://lnkd.in/eZ9eHrkA